MedTrace Logo

Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A

NCT01683773 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-09-17

No results posted yet for this study

Summary

This trial will investigate the administration of two new tuberculosis vaccines, called AERAS-402 and MVA85A. The purpose of this trial is to assess what happens when both of these vaccines are given one after the other. The trial will assess the safety of both vaccines and also their ability to stimulate an immune response within the body. It is hoped that when these two vaccines are given in sequence, the combined immune response is even better than when each vaccine is used individually.

Conditions

Interventions

BIOLOGICAL

AERAS-402

Intramuscular needle injection 1x10\^11 vp

BIOLOGICAL

MVA85A

Intradermal needle injection 1x10\^8 pfu

Sponsors & Collaborators

  • Aeras

    collaborator OTHER

  • Crucell Holland BV

    collaborator INDUSTRY

  • Emergent BioSolutions

    collaborator INDUSTRY

  • University of Birmingham

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Helen McShane · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01683773 on ClinicalTrials.gov